Matches in SemOpenAlex for { <https://semopenalex.org/work/W2601064488> ?p ?o ?g. }
Showing items 1 to 91 of
91
with 100 items per page.
- W2601064488 abstract "e15529 Background: Patients (pts) with GCT who fail to be cured following multiple chemotherapy (CT) courses (± high-dose CT) have an extremely poor prognosis and long-term remissions are anecdotal. Pazopanib (PZP) is a potent and selective, orally available, TKI of VEGFR1, 2, and 3, PDGFRα, PDGFRβ, and cKit. We updated the initial results of the ongoing open-label, single-group, phase 2 study which is sponsored by INT Milano. Methods: Patients failing at least 2 platinum-based CT (including high-dose CT) received PZP 800 mg/day orally until disease progression (PD) or evidence of unacceptable toxicity/side effects. All pts underwent measurement of serum tumor markers (STM), a computed tomography and a FDG-PET after 1 month and q2 months thereafter. In a Simon’s 2-stage design, the primary endpoint is 3-month progression-free survival (PFS). In stage 1, 18 evaluable patients will be accrued. If ≥ 3 pts will be progression-free at 3 months, enrolment will be extended to the 2ndstage. Results: From 06 to 12..." @default.
- W2601064488 created "2017-04-07" @default.
- W2601064488 creator A5004236203 @default.
- W2601064488 creator A5012466586 @default.
- W2601064488 creator A5021777698 @default.
- W2601064488 creator A5024954730 @default.
- W2601064488 creator A5028798959 @default.
- W2601064488 creator A5030934542 @default.
- W2601064488 creator A5044990634 @default.
- W2601064488 creator A5057006069 @default.
- W2601064488 creator A5058115974 @default.
- W2601064488 creator A5058849092 @default.
- W2601064488 creator A5067994961 @default.
- W2601064488 creator A5080549125 @default.
- W2601064488 creator A5080811290 @default.
- W2601064488 creator A5083331837 @default.
- W2601064488 creator A5085121255 @default.
- W2601064488 creator A5090061046 @default.
- W2601064488 creator A5090715927 @default.
- W2601064488 date "2014-05-20" @default.
- W2601064488 modified "2023-10-17" @default.
- W2601064488 title "Pazopanib in chemoresistant patients with germ cell tumors (GCT): Updated results of the open-label, single-group, phase 2 Pazotest-01 trial." @default.
- W2601064488 doi "https://doi.org/10.1200/jco.2014.32.15_suppl.e15529" @default.
- W2601064488 hasPublicationYear "2014" @default.
- W2601064488 type Work @default.
- W2601064488 sameAs 2601064488 @default.
- W2601064488 citedByCount "1" @default.
- W2601064488 countsByYear W26010644882016 @default.
- W2601064488 crossrefType "journal-article" @default.
- W2601064488 hasAuthorship W2601064488A5004236203 @default.
- W2601064488 hasAuthorship W2601064488A5012466586 @default.
- W2601064488 hasAuthorship W2601064488A5021777698 @default.
- W2601064488 hasAuthorship W2601064488A5024954730 @default.
- W2601064488 hasAuthorship W2601064488A5028798959 @default.
- W2601064488 hasAuthorship W2601064488A5030934542 @default.
- W2601064488 hasAuthorship W2601064488A5044990634 @default.
- W2601064488 hasAuthorship W2601064488A5057006069 @default.
- W2601064488 hasAuthorship W2601064488A5058115974 @default.
- W2601064488 hasAuthorship W2601064488A5058849092 @default.
- W2601064488 hasAuthorship W2601064488A5067994961 @default.
- W2601064488 hasAuthorship W2601064488A5080549125 @default.
- W2601064488 hasAuthorship W2601064488A5080811290 @default.
- W2601064488 hasAuthorship W2601064488A5083331837 @default.
- W2601064488 hasAuthorship W2601064488A5085121255 @default.
- W2601064488 hasAuthorship W2601064488A5090061046 @default.
- W2601064488 hasAuthorship W2601064488A5090715927 @default.
- W2601064488 hasConcept C121608353 @default.
- W2601064488 hasConcept C126322002 @default.
- W2601064488 hasConcept C126894567 @default.
- W2601064488 hasConcept C141071460 @default.
- W2601064488 hasConcept C143998085 @default.
- W2601064488 hasConcept C146357865 @default.
- W2601064488 hasConcept C151730666 @default.
- W2601064488 hasConcept C203092338 @default.
- W2601064488 hasConcept C2776694085 @default.
- W2601064488 hasConcept C2776938808 @default.
- W2601064488 hasConcept C2778439243 @default.
- W2601064488 hasConcept C2779256057 @default.
- W2601064488 hasConcept C2779490328 @default.
- W2601064488 hasConcept C2780739268 @default.
- W2601064488 hasConcept C29730261 @default.
- W2601064488 hasConcept C31760486 @default.
- W2601064488 hasConcept C535046627 @default.
- W2601064488 hasConcept C71924100 @default.
- W2601064488 hasConcept C86803240 @default.
- W2601064488 hasConceptScore W2601064488C121608353 @default.
- W2601064488 hasConceptScore W2601064488C126322002 @default.
- W2601064488 hasConceptScore W2601064488C126894567 @default.
- W2601064488 hasConceptScore W2601064488C141071460 @default.
- W2601064488 hasConceptScore W2601064488C143998085 @default.
- W2601064488 hasConceptScore W2601064488C146357865 @default.
- W2601064488 hasConceptScore W2601064488C151730666 @default.
- W2601064488 hasConceptScore W2601064488C203092338 @default.
- W2601064488 hasConceptScore W2601064488C2776694085 @default.
- W2601064488 hasConceptScore W2601064488C2776938808 @default.
- W2601064488 hasConceptScore W2601064488C2778439243 @default.
- W2601064488 hasConceptScore W2601064488C2779256057 @default.
- W2601064488 hasConceptScore W2601064488C2779490328 @default.
- W2601064488 hasConceptScore W2601064488C2780739268 @default.
- W2601064488 hasConceptScore W2601064488C29730261 @default.
- W2601064488 hasConceptScore W2601064488C31760486 @default.
- W2601064488 hasConceptScore W2601064488C535046627 @default.
- W2601064488 hasConceptScore W2601064488C71924100 @default.
- W2601064488 hasConceptScore W2601064488C86803240 @default.
- W2601064488 hasLocation W26010644881 @default.
- W2601064488 hasOpenAccess W2601064488 @default.
- W2601064488 hasPrimaryLocation W26010644881 @default.
- W2601064488 isParatext "false" @default.
- W2601064488 isRetracted "false" @default.
- W2601064488 magId "2601064488" @default.
- W2601064488 workType "article" @default.